Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results November 25, 2024 +3 900 people with mild to moderate Alzheimer’s disease. Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1 NYT NYT > Business NYTimes 900 people with mild to moderate Alzheimer’s disease. Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1 NYT NYT > Business NYTimes